Proteolysis Targeting Chimeras for the Selective Degradation of Mcl-1/Bcl-2 Derived from Nonselective Target Binding Ligands.
Ziqian WangNianzhe HeZongwei GuoCuili NiuTing SongYafei GuoKeke CaoAnhui WangJunjie ZhuXiaodong ZhangZhichao ZhangPublished in: Journal of medicinal chemistry (2019)
Proteolysis targeting chimera (PROTAC) recruits an E3 ligase to a target protein to induce its ubiquitination and subsequent degradation. We reported success in the development of two PROTACs (C3 and C5) that potently and selectively induce the degradation of Mcl-1 and Bcl-2 (DC50 = 0.7 and 3.0 μM), respectively, by introducing the E3 ligase cereblon-binding ligand pomalidomide to Mcl-1/Bcl-2 dual inhibitors S1-6 and Nap-1 with micromolar-range affinity. C3-induced Mcl-1 ubiquitination translated into much more lethality in Mcl-1-dependent H23 cells than the most potent Mcl-1 occupancy-based inhibitor A-1210477 with nanomolar-range affinity. Moreover, structure-activity relationship analysis and molecular dynamic simulations discovered the structural basis for turning nonselective or promiscuous Bcl-2 family ligands into selective PROTACs. C3 and C5 exhibited reversible depletion in living cells, which provides a new potent toolkit for gain-of-function studies to probe the dynamic roles of Bcl-2 and Mcl-1 in apoptosis networks.
Keyphrases
- living cells
- cell cycle arrest
- structural basis
- induced apoptosis
- single molecule
- structure activity relationship
- cell death
- endoplasmic reticulum stress
- cancer therapy
- immune response
- high glucose
- cell proliferation
- binding protein
- dendritic cells
- quantum dots
- dna binding
- signaling pathway
- pi k akt
- multiple myeloma
- transcription factor
- protein protein